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Abstract
AIM: To investigate M2 isoform of pyruvate kinase 
(PKM2) expression in gastric cancers and evaluate its 
potential as a prognostic biomarker and an anticancer 
target.
METHODS: All tissue samples were derived from gas-
tric cancer patients underwent curative gastrectomy as 
a primary treatment. Clinical and pathological informa-
tion were obtained from the medical records. Gene ex-
pression microarray data from 60 cancer and 19 non-
cancer gastric tissues were analyzed to evaluate the 
expression level of PKM2 mRNA. Tissue microarrays 
were constructed from 368 gastric cancer patients. 
Immunohistochemistry was used to measure PKM2 ex-
pression and PKM2 positivity of cancer was determined 
by proportion of PKM2-positive tumor cells and stain-
ing intensity. Association between PKM2 expression 
and the clinicopathological factors was evaluated and 
the correlation between PKM2 and cancer prognosis 
was evaluated.
RESULTS: PKM2 mRNA levels were increased more 
than 2-fold in primary gastric cancers compared to 
adjacent normal tissues from the same patients (log 
transformed expression level: 7.6 ± 0.65 vs  6.3 ± 0.51, 
P  < 0.001). Moreover, differentiated type cancers had 
significantly higher PKM2 mRNA compared to undif-
ferentiated type cancers (log transformed expression 
level: 7.8 ± 0.70 vs  6.7 ± 0.71, P  < 0.001). PKM2 pro-
tein was mainly localized in the cytoplasm of primary 
cancer cells and detected in 144 of 368 (39.1%) hu-
man gastric cancer cases. PKM2 expression was not 
related with stage (P  = 0.811), but strongly correlated 
with gastric cancer differentiation (P  < 0.001). Differ-
entiated type cancers expressed more PKM2 protein 
than did the undifferentiated ones. Well differentiated 
adenocarcinoma showed 63.6% PKM2-positive cells; in 
contrast, signet-ring cell cancers showed only 17.7% 
PKM2-positive cells. Importantly, PKM2 expression was 
correlated with shorter overall survival (P  < 0.05) inde-
pendent of stage only in signet-ring cell cancers.
CONCLUSION: PKM2 expression might be an adverse 
prognostic factor for signet-ring cell carcinomas. Its 
function and potential as a prognostic marker should 
be further verified in gastric cancer.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Gastric cancer is the second leading cause of  cancer-
related deaths worldwide[1]. Although surgery is the stan-
dard curative treatment for gastric cancer, relapses occur 
in many patients even after adjuvant therapy. Gastric 
cancer patients with the same stage of  the disease pres-
ent different clinical courses and have different progno-
sis[2]. This heterogeneity of  gastric cancer is present at 
the molecular level and has a genetic predisposition to 
it[3-6]. Therefore, it is important to identify new molecular 
markers to predict patients’ outcomes and personalize 
treatments according to the individual biology of  each 
cancer.
Cancer cells take up glucose at higher rates than do 
normal cells but produce energy mainly by glycolysis, 
rather than by mitochondrial oxidation of  pyruvate[7]. 
This process, called aerobic glycolysis or the Warburg ef-
fect, is very important for tumor growth[8]. Glycolysis in-
creases lactate production resulting in acidification of  the 
extracellular environment, which is believed to facilitate 
cell invasion and metastasis[9]. The M2 isoform of  pyru-
vate kinase (PKM2) was identified as a driver of  aerobic 
glycolysis, and has been shown to be the isoform prefer-
entially overexpressed in tumor cells[10]. Other isoenzymes 
of  pyruvate kinase (pyruvate kinase type M1, pyruvate 
kinase type L, pyruvate kinase type R) are expressed de-
pending upon the metabolic responsibilities of  the vari-
ous non-cancerous cells and tissues[10].
Several studies have shown that PKM2 is selectively 
stained in cancer cells in immunohistochemical as-
say[11,12]. It has been suggested that plasma PKM2 could 
be a valuable tumor marker for diagnosis or monitoring 
of  lung, pancreas, kidney, breast, tongue, and gastroin-
testinal cancers[11-17]. However, little is known about the 
biological function of  PKM2 in cancer and its potential 
as an anti-cancer target. Previous studies reported that 
PKM2 protein level was increased in both the tumors 
and plasma of  gastric cancer patients[17], and that it 
positively correlated with cisplatin sensitivity in gastric 
cancer cell lines[18]. However, clinical and prognostic 
implications of  PKM2 as a marker for gastric cancer are 
still unclear. Therefore, we decided to analyze whether 
PKM2 expression is correlated with cancer progression 
and prognosis in human gastric cancer patients. 
MATERIALS AND METHODS
Gene expression microarray data analysis
The previously generated gene expression data from 60 
gastric cancer patients is available in the NCBI’s GEO 
public database (microarray data accession number, 
GSE13861)[2]. All patients underwent curative gastrecto-
my as a primary treatment in 2005 at Severance Hospital, 
Yonsei University College of  Medicine, Seoul, South Ko-
rea. Clinical and pathologic data were obtained by review 
of  the Severance Hospital medical records. The gene 
expression data of  60 cancer and 19 non-cancer gastric 
tissues from 60 gastric cancer patients were analyzed. 
Class comparison using two sample t test (significance P 
< 0.001, 10 000 random permutation) identified gastric 
cancer specific genes. 
Patients and tissues
We selected primary gastric adenocarcinoma patients 
who had undergone curative gastrectomy as the primary 
treatment between 1999 and 2007 at Gangnam Severance 
Hospital, Yonsei University College of  Medicine, Seoul, 
South Korea. Patients were followed up more than 36 
mo after surgery or presented recurrence or death within 
36 mo after surgery. We obtained paraffin-embedded tis-
sues and clinical data from patients. The demographic 
details of  the cases analyzed are described in Table 1. 
Clinical and pathological information were obtained from 
the medical records. Tumors were staged according to 
the 7th edition of  the American Joint Committee Guide-
lines on cancer staging issued in 2010. Tumor histology 
was classified as differentiated (well and moderately dif-
ferentiated adenocarcinoma) and undifferentiated (poorly 
differentiated adenocarcinoma and signet ring cell car-
cinoma) type. The median follow-up duration was 70.6 
mo (range: 3.6-144.6 mo). A total of  125 (34%) patients 
did not receive any adjuvant chemotherapy, and most of  
their cancers were classified as stage Ⅰ. No radiation was 
given to any of  the patients. The study was approved by 
the Investigational Review Board of  Gangnam Severance 
Hospital.
Tissue microarray construction and immunohistochemistry
The paraffin-embedded tissue microarray blocks of  gas-
tric cancer tissue specimens obtained from 368 patients 
were used. Each block had a 3-mm core of  gastric can-
cer tissue. Immunohistochemistry was performed on 4 
μm-thick tissue microarray tissue sections an Enzyme-
conjugated polymer backbone: Dextran (EnVision De-
tection kit, DAKO Cytomation, Glostrup, Denmark) 
according to the manufacturer’s instructions after 
microwave-based antigen retrieval. Antibody to PMK2 
1:500, Cell Signaling, Cambridge, MA, United States) 
was applied to the sections, which were incubated for 
2 h at room temperature. The sections were incubated 
with secondary antibody (HRP-Rabbit/Mouse) for 15 
min at room temperature, and developed using a Nova-
RED substrate kit (VECTOR Laboratory, Burlingame, 
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CA, United States) and counterstained with Harris he-
matoxylin. The slides were photographed using a Zeiss 
microscope. The degree of  immunostaining was scored 
independently by 2 observers based on the proportion 
of  positively stained tumor cells and the intensity of  
staining. Tumor cell proportion was classified as follows: 
0%, 10%-25%, 25%-50%, and > 50% PKM2-positive 
tumor cells. Staining intensity was classified as none, 
weak and strong staining. 
We measured PKM2 expression in non-cancer gastric 
epithelial cells and malignant lesions. Tumors with more 
than 25% PKM2-positive cells were considered tumors 
with positive PKM2 expression, and those with less than 
25% PKM2-positive cells were considered negative for 
PKM2 expression.
Statistical analysis
The correlation between the immunohistochemical ex-
pression scores and patient survival after surgery was es-
timated using the Kaplan-Meier method, followed by uni-
variate comparison between the groups using the log-rank 
test. To adjust for potential confounding variables and to 
single out independent predictors of  survival, a multivari-
ate analysis of  survival was done using the Cox’s pro-
portional hazard model using a forward stepwise mode. 
Statistical analyses were done with GraphPad Prism 5 
(GraphPad Software, San Diego, CA) and PASW Statis-
tics 18.0 (SPSS Inc., Chicago, IL). Association between 
PKM2 expression and the clinicopathological factors 
was tested using the χ 2 test. Two-tailed P values of  0.05 
or less were considered statistically significant.
RESULTS
Upregulation of PKM2 mRNA in primary gastric cancers
From sixty gastric cancer patients, 60 gastric cancer tis-
sues and 19 non-cancer adjacent gastric tissues were 
used for gene expression microarray analysis. PKM2 was 
identified as one of  3360 gastric cancer-specific genes 
by class comparison using the 2-sample t test (Data not 
shown). PKM2 mRNA levels were increased > 2-fold 
in human primary gastric cancers compared to normal 
adjacent tissues from the same patients (log transformed 
expression level: 7.6 ± 0.65 vs 6.3 ± 0.51, P < 0.001, Fig-
ure 1A). Among cancer types, differentiated type cancers 
displayed > 2-fold increase in PKM2 levels compared to 
undifferentiated type cancers (log transformed expression 
level: 7.8 ± 0.70 vs 6.7 ± 0.71, P < 0.001, Figure 1B). 
Overexpression of PKM2 in primary gastric cancer
To examine whether PKM2 protein upregulation was 
linked to the clinical characteristics of  gastric cancers, 
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AJCC: American Joint Committee on Cancer; T: Tumor; N: Node.
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Table 1  Correlation between the M2 isoform of pyruvate kinase expression and clinicopathologic characteristics of gastric 
cancer patients  n  (%)
Characteristics M2 isoform of pyruvate kinase expression
Total (n = 368) Negative (n = 224) Positive (n  = 144) P
Median follow-up (70.6 mo)
   Relapse 143 (39.0)
   Death 138 (37.7)
   Adjuvantchemotherapy 243 (66.0)
Age (yr) 0.027
   ≤ 60                  230 150 (65.2) 80 (34.8)
   > 60                  138    74 (53.6) 64 (46.4)
Gender 0.263
   Male                  222 130 (58.6) 92 (41.4)
   Female                  146   94 (64.4) 52 (35.6)
AJCC 7th stage 0.811
   Ⅰ                  105   67 (63.8) 38 (36.2)
   Ⅱ                    89   51 (57.3) 38 (42.7)
   Ⅲ                  172 105 (61.0) 67 (39.0)
   Ⅳ                      2     1 (50.0)   1 (50.0)
T stage 0.009
   T1                    94   62 (65.9) 32 (34.1)
   T2                    42    30 (71.4) 12 (28.6)
   T3                    87   40 (45.9) 47 (54.1)
   T4                  145   92 (63.4) 53 (36.6)
N stage 0.086
   N0                  131   80 (61.1) 51 (38.9)
   N1                    62   33 (53.2) 29 (46.8)
   N2                    69   37 (53.6) 32 (46.4)
   N3                  106   74 (69.8) 32 (30.2)
Histology < 0.001
   Welldifferentiatedadenocarcinoma                    22     8 (36.4) 14 (63.6)
   Moderatelydifferentiatedadenocarcinoma                    96   39 (40.6) 57 (59.4)
   Poorlydifferentiatedadenocarcinoma                  143   91 (63.6) 52 (36.4)
   Signetringcellcarcinoma                    79   65 (82.3) 14 (17.7)
the following samples were subjected to immunohisto-
chemistry with a human PKM2 antibody: 368 paraffin-
embedded, archived gastric cancer tissue samples, in-
cluding 194 cases of  stages Ⅰ/Ⅱ and 174 cases of  stage 
Ⅲ/Ⅳ tumors. The results are summarized in Table 1. 
PKM2 protein was detected in 144 of  368 (39.1%) hu-
man gastric cancer cases. Strong cytoplasmic staining 
of  PKM2 was detected in 42 (11.4%) tumors and weak 
staining was detected in 102 (27.7%) tumors. As shown 
in Figure 2, PKM2 was mainly localized in the cytoplasm 
of  primary cancer cells. Diffuse and/or intense cytoplas-
mic statining was noted in only cancer cells. In contrast, 
PKM2 was either undetectable or only marginally detect-
able in the normal epithelial body gland of  noncancer-
ous tissues in the adjacent section regions (Figure 2). 
Relationship between PKM2 expression and the clinical 
features of gastric cancers
As shown in Table 1, there was no correlation between 
stage and PKM2 expression (P = 0.811). PKM2 expres-
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Figure 1  Expression level of the M2 isoform of pyruvate kinase mRNA by gene expression microarray. A: The M2 isoform of pyruvate kinase (PKM2) up-reg-
ulation in the 18 primary gastric cancers compared to gastric adjacent noncancerous tissues paired from the same patient (P < 0.001); B: PKM2 up-regulation in the 
22 differentiated type (D) gastric cancers compared to 27 undifferentiated type (UD) gastric cancers (P < 0.001). The column and bar represent mean and standard 
deviation, respectively.
100 μm
A B
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Figure 2  Representative images from immunohistochemistry assays of 368 archived gastric cancer cases at 20 × 10 magnification. A: Moderately differenti-
ated adenocarcinoma and negative for the M2 isoform of pyruvate kinase (PKM2) expression; B: Signet ring cell carcinoma and negative for PKM2 expression; C: 
Moderately differentiated adenocarcinoma and positive for PKM2 expression; D: Signet ring cell carcinoma and positive for PKM2 expression.
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sion was strongly correlated with gastric cancer differen-
tiation (P < 0.001). Differentiated type cancers expressed 
more PKM2 protein than did the undifferentiated ones. 
Well differentiated adenocarcinoma showed 63.6% PKM2- 
positive cells; in contrast, signet-ring cell cancers showed 
only 17.7% PKM2-positive cells. 
Association between PKM2 expression and patient 
prognosis
We evaluated whether PKM2 expression could be a prog-
nostic factor for gastric cancer. Two out of  368 patients 
died of  non-cancer and were excluded from analysis. 
Table 2 shows that recurrence-free survival (RFS) and 
overall survival (OS) are significantly different between 
patients with different clinical stage (P < 0.001), T clas-
sification (P < 0.001), and N classification (P < 0.001). 
There was no significant difference in prognosis accord-
ing to PKM2 expression. 
We performed subgroup analysis at each tumor stage. 
In stages Ⅱ or Ⅲ patients, PKM2 expression showed 
no significant correlation with RFS or OS. However, in 
stage Ⅰ early gastric cancer patients (n = 99), PKM2 ex-
pression was significantly correlated with poor RFS (P = 
0.006) and OS (P = 0.015). Based on the observation that 
PKM2 expression rate was remarkably different accord-
ing to cancer histology (Table 1), the prognostic value of  
PKM2 expression in patient subgroups was evaluated ac-
cording to the histology. We found that in signet-ring cell 
carcinomas PKM2 expression correlated with poor prog-
nosis (P = 0.042 for OS, Table 3 and Figure 3). Moreover, 
univariate and multivariate analyses showed that PKM2 
expression, as well as clinical stage, were independent 
prognostic factors for survival (Table 3). 
DISCUSSION
In this study, we report the characterization of  PKM2 
expression in human gastric cancers, and present its cor-
relation with clinicopathological parameters and patients’ 
prognosis. First, our study revealed that PKM2 is overex-
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  Characteristics RFS OS
HR (95% CI)  P  value HR (95% CI)  P  value
  Age (yr)
     ≤ 60
     > 60  1.12 (0.80-1.57)     0.488  1.16 (0.83-1.64)       0.373
  Gender
     M
     F  1.18 (0.85-1.65)     0.315  1.09 (0.78-1.53)       0.600
  PKM2 
     Negative
     Positive  0.93 (0.66-1.32)     0.713  0.92 (0.65-1.30)       0.637
  T stage
     T1/2/3
     T4  6.12 (4.25-8.81)  < 0.001  5.04 (3.51-7.22)   < 0.001
  N stage
     N0/1/2
     N3  6.02 (4.29-8.46)  < 0.001  5.64 (4.01-7.95)   < 0.001
  Stage 
    Ⅰ/Ⅱ
     Ⅲ  8.42 (5.48-12.94)  < 0.001  6.70 (4.41-10.16)   < 0.001
Table 2  Prognosis analysis of recurrence-free survival and 
overall survival of total patients (n  = 366)
RFS: Recurrence-free survival; OS: Overall survival; HR: Hazard ratio; 
PKM2: The M2 isoform of pyruvate kinase; T: Tumor; N: Node; 95% CI: 95% 
confidence interval.
  Characteristics Groups HR (95% CI) P  value
  Univariate analysis
     Age (yr) > 60 vs ≤ 60  1.11 (0.52-2.37)      0.785
     Gender F vs M  1.08 (0.56-2.07)      0.817
     PKM2 Positive vs negative  2.13 (1.02-4.44)      0.042
     T stage T4 vs T1/2/3  6.25 (3.03-12.85)  < 0.001
     N stage N3 vs N0/1/2  5.70 (2.90-11.22)  < 0.001
     Stage Ⅲ vsⅠ/Ⅱ  6.84 (2.83-16.53)  < 0.001
  Multivariate analysis
     PKM2 Positive vs negative  2.12 (1.02-4.42)      0.044
     Stage Ⅲ vsⅠ/Ⅱ  6.84 (2.83-16.55)  < 0.001
Table 3  Univariate and multivariate analysis of overall sur-
vival in signet ring cell carcinoma (n  = 79)
HR: Hazard ratio; PKM2: The M2 isoform of pyruvate kinase; 95% CI: 95% 
confidence interval; F: Female; M: Male; T: Tumor; N: Node.
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Figure 3  Recurrence-free survival (A) and overall survival (B) curves ac-
cording to the M2 isoform of pyruvate kinase expression in signet ring 
cell gastric cancer after curative resection (n = 79). Positive M2 isoform of 
pyruvate kinase (PKM2) expression, real line; Negative PKM2 expression, dot-
ted line.
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pressed in gastric cancers both at the mRNA and protein 
levels compared to normal gastric tissues. Well and mod-
erately differentiated adenocarcinoma showed signifi-
cantly higher expression of  PKM2 (60% PKM2-positive 
cells); in contrast, signet-ring cell cancers showed only 
17.7% PKM2-positive cells (Table 1). Because PKM2 is 
mainly localized in the cytoplasm of  primary cancer cells 
and signet-ring cells contain a large amount of  mucin 
and scanty cytoplasm, we hypothesize that this might ex-
plain the lower levels of  PKM2 expression in these cells. 
This finding might be explained by the different glucose 
utilization rates of  the various gastric cancer subtypes. 
Fluorine-18 fluoro deoxy-D-glucose positron emission 
tomography detected glucose uptake of  tumor cells, and 
differentiated gastric cancers showed higher fluoro deoxy-
D-glucose uptake rates than did undifferentiated ones[19]. 
Second, PKM2 protein expression was found to ne-
gatively correlate with survival in signet-ring cell gastric 
cancer patients, as higher expression of  PKM2 is associ-
ated with patients’ shorter survival time (P = 0.042) after 
curative resection (Figure 3). Signet-ring cell carcinomas 
have a distinct biology and generally have worse progno-
sis than do other types of  gastric cancer[20]. A recent study 
reported that higher glucose uptake was indicative of  a 
more aggressive disease especially in advanced signet-ring 
cell cancers[21], although no biological mechanism was 
proposed to explain it. This finding is in agreement with 
our results. Thus, our study suggests that higher PKM2 
expression, which indicates a higher rate of  glycolysis in 
the tumor, might represent a novel prognostic marker for 
the clinical outcome of  these types of  gastric cancers.
PKM2 expression was related with poor prognosis 
only in stage Ⅰ gastric cancer patients who did not receive 
chemotherapy. Only 4 of  99 patients showed relapse after 
curative gastrectomy, and in all cases, cancer cells were 
positive for PKM2 expression compared to the 36% 
patients overall who expressed PKM2. Furthermore, 3 
patients had early relapses, within 1 year from the surgery, 
and all expressed high levels of  PKM2 in the resected 
tissues. As cancer relapse in stage Ⅰ patients are rare and 
four recurrent cases in our result are small number, it 
seems too early to conclude that PKM2 expression corre-
lated with poor prognosis of  stage Ⅰ gastric cancer. How-
ever, it is clinical value to expand investigation in large 
cases. For stages Ⅱ and Ⅲ patients, there were no signifi-
cant differences in survival. In a previous study, PKM2 
was shown to positively correlate with the response to 
cisplatin in human gastric cancer cell lines[18]. Cisplatin is 
the main chemotherapeutic agent for gastric cancers as 
either adjuvant or palliative aim. As cisplatin was admin-
istered as adjuvant therapy to 62.8% (147/234) of  stages 
Ⅱ or Ⅲ gastric cancer patients after curative gastrectomy, 
the negative prognostic effect of  PKM2 might be can-
celled by cisplatin-based chemotherapy.
The possibility of  using PKM2 as a target for the 
development of  anti-cancer therapies has been evaluated 
in the preclinical setting[22,23]. PKM2 knockdown by short 
hairpin RNA reduced the ability of  human cancer cell 
lines to form tumors in nude mouse xenografts[10,24]. If  
anti-cancer strategies based on targeting PKM2 treatment 
are feasible, stage Ⅰ or signet-ring cell cancer patients with 
PKM2 expression would be suitable candidates for such 
treatments. 
The molecular function of  PKM2 and its role in can-
cer are not completely understood yet. It was recently 
shown that PKM2 allows cancer cells to mount an anti-
oxidant response and thereby support cell survival under 
acute oxidative stress[25] and also induces epidermal growth 
factor receptor (EGFR)-dependent β-catenin transactiva-
tion, which leads to cell proliferation and tumorigenesis[26]. 
These data are in agreement with our microarray study in 
which we also identified EGFR and β-catenin signaling, 
and hypoxic stress are linked to gastric cancer. Altogether, 
these studies suggest that the function of  PKM2 in gastric 
cancer is very complex and needs to be further elucidated. 
In addition, the mechanisms of  the regulation of  PKM2 
expression specifically in gastric tumors should be studied.
In conclusion, this study showed that PKM2 was 
overexpressed in gastric cancers. Moreover, PKM2 ex-
pression is an independent prognostic factor for signet 
ring cell carcinomas. The biological role of  PKM2 in the 
development of  these tumors needs to be further eluci-
dated. 
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